Neola Medical AB (publ) (STO:NEOLA)
Sweden · Delayed Price · Currency is SEK 0.5200
+0.0100 (1.96%)
Sep 4, 2026, 2:45 PM CET
Neola Medical AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | - | - | - | - | - | 0.63 |
Other Revenue | 0.04 | 0.04 | 0.05 | 0.04 | 0.3 | 0.74 |
| 0.04 | 0.04 | 0.05 | 0.04 | 0.3 | 1.37 | |
Revenue Growth | -26.92% | -26.92% | 26.83% | -86.51% | -77.79% | 17.21% |
Cost of Revenue | 0.17 | 0.27 | 1.37 | 1.77 | 1.42 | 1.33 |
Gross Profit | -0.13 | -0.24 | -1.32 | -1.72 | -1.12 | 0.04 |
Selling, General & Admin | 21.18 | 17.7 | 18.23 | 16.09 | 17.64 | 16.39 |
Other Operating Expenses | -10.03 | -8.22 | -10.28 | -9.78 | -9.41 | -9.72 |
Operating Expenses | 12.55 | 10.86 | 9.48 | 7.9 | 9 | 6.69 |
Operating Income | -12.68 | -11.1 | -10.8 | -9.63 | -10.12 | -6.65 |
Interest Expense | -0.19 | -0.19 | - | - | - | - |
Interest & Investment Income | 0.17 | 0.26 | 0.73 | 0.61 | 0.03 | - |
Currency Exchange Gain (Loss) | 0.01 | 0.01 | - | 0 | - | - |
Other Non Operating Income (Expenses) | - | - | - | - | -0 | - |
EBT Excluding Unusual Items | -12.7 | -11.02 | -10.06 | -9.01 | -10.09 | -6.65 |
Asset Writedown | - | - | - | - | -0.27 | - |
Pretax Income | -12.7 | -11.02 | -10.06 | -9.01 | -10.35 | -6.65 |
Net Income | -12.7 | -11.02 | -10.06 | -9.01 | -10.35 | -6.65 |
Net Income to Common | -12.7 | -11.02 | -10.06 | -9.01 | -10.35 | -6.65 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 78 | 76 | 70 | 56 | 26 | 14 |
Shares Outstanding (Diluted) | 78 | 76 | 70 | 56 | 26 | 14 |
Shares Change | 6.82% | 8.93% | 25.80% | 113.90% | 86.03% | 48.67% |
EPS (Basic) | -0.16 | -0.14 | -0.14 | -0.16 | -0.40 | -0.47 |
EPS (Diluted) | -0.16 | -0.14 | -0.14 | -0.16 | -0.40 | -0.47 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -11.12 | -11.07 | -10.92 | -6.54 | -8.6 | -7.1 |
Free Cash Flow Per Share | -0.14 | -0.14 | -0.16 | -0.12 | -0.33 | -0.51 |
Gross Margin | - | - | - | - | - | 2.85% |
Operating Margin | -33373.68% | -29210.53% | -20765.39% | -23478.05% | -3328.62% | -485.98% |
Profit Margin | -33418.42% | -29005.26% | -19353.85% | -21975.61% | -3405.59% | -485.98% |
Free Cash Flow Margin | -29268.42% | -29131.58% | -20992.31% | -15956.10% | -2828.95% | -518.77% |
EBITDA | -11.28 | -9.72 | -9.4 | -8.19 | -9.55 | -6.64 |
D&A For EBITDA | 1.4 | 1.39 | 1.39 | 1.43 | 0.57 | 0.02 |
EBIT | -12.68 | -11.1 | -10.8 | -9.63 | -10.12 | -6.65 |
Revenue as Reported | 10.14 | 8.33 | 10.39 | - | 9.75 | 11.1 |